Abstract
BackgroundImmune checkpoint inhibitors (ICI) have anti-cancer activity in selected patients with central nervous system (CNS) metastases. However, the benefit of ICIs in patients with leptomeningeal metastases (LMM) is unknown. We...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have